CC-486 and Venetoclax for Acute Myeloid Leukemia

  • STATUS
    Recruiting
  • End date
    Mar 20, 2029
  • participants needed
    22
  • sponsor
    University of Colorado, Denver
Send
Updated on 20 April 2022
See if I qualify

Summary

This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.

Description

Subjects confirmed eligible will be admitted to the hospital for cycle 1, day 1. Venetoclax will be administered days 1-3, with the following schema:

100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter.

Subjects taking concomitant CYP3A4 inhibitors will be given the appropriate reduced doses of venetoclax.

Subjects will be monitored inpatient for tumor lysis syndrome (TLS) for at least 24 hours after administration of the venetoclax target dose. Venetoclax will continue at 400 mg daily until day 28, the completion of cycle 1.

During dose escalation, subjects will be accrued into two cohorts using two different doses of CC-486 (cohort 1=200 mg, cohort 2=300 mg, both to be administered orally on days 1-14 of a 28-day cycle).

Two bone marrow biopsies will be performed during the first cycle: day 4 or 5 (+2 days), and day 28. The day 28 bone marrow will be used for efficacy purposes. Subsequent cycles will have response assessment bone marrow biopsies day 28 of every cycle for subjects who have not responded (CR/CRi/MLFS); after a response occurs (CR/CRi/MLFS), subjects will have bone marrow biopsies on day 28 of every 3rd cycle until they have been on the study for one year, at which point they will have a bone marrow biopsy every 6 months until study discontinuation.

Once the MTD is established, or in the absence of an MTD, a recommendation for a CC-486 dose with venetoclax is made, the study will progress to the expansion phase. For the expansion phase, 10 subjects will be recruited. These will be patients with relapsed/refractory (R/R) disease who have never received venetoclax. On day 1 of cycle 1, subjects will receive CC-486 at the MTD or recommended CC-486 dose as determined from Phase I, and this will continue daily through day 14. Venetoclax will be dose escalated, as above, from 100 to 200 to 400 mg on days 1, 2 and 3, respectively, with inpatient monitoring for TLS, and with appropriate dose reduction if administered with a CYP3A4 inhibitor. Bone marrow biopsies will occur on day 4 or 5 (+2) and on day 28 of cycle 1. Subsequent response assessment bone marrow biopsies will occur on day 28 of every 3rd cycle for subjects who have achieved a response for 1 year from study entry and then every 6 months until study discontinuation, or on day 28 of every treatment cycle for subjects who do not achieve a response.

Details
Condition AML
Treatment CC-486, venetoclax
Clinical Study IdentifierNCT05287568
SponsorUniversity of Colorado, Denver
Last Modified on20 April 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Subject must have confirmation of non-APL AML by WHO criteria46 and have undergone at least one line of therapy (dose escalation and dose expansion cohorts)
Transplant eligible patients can participate in the study and they are allowed to proceed with stem cell transplantation at any time during the study
Subject must have a projected life expectancy of at least 12 weeks
Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 2\
Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula
Subject must have adequate liver function as demonstrated by
aspartate aminotransferase (AST) ≤ 3.0 × ULN
alanine aminotransferase (ALT) ≤ 3.0 × ULN
bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome Unless considered due to leukemic organ involvement
Non-sterile male subjects must use contraceptive methods with partner(s) at least
prior to beginning study drug administration and continuing up to 90 days
after the last dose of study drug. Male subjects must agree to refrain from
sperm donation from initial study drug administration until 90 days after the
last dose of study drug. No contraception is required if male subjects are
surgically sterile (vasectomy with medical assessment confirming surgical
success) or if the male subject has a female partner who is postmenopausal or
permanently sterile (bilateral oophorectomy, bilateral salpingectomy or
hysterectomy)
Female subjects must be either
Postmenopausal; defined as Age > 60 years with no menses for 12 or more months without an alternative medical cause; OR
Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); OR
If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose
Subject must voluntarily sign and date an informed consent, approved by an
Institutional Review Board (IRB), prior to the initiation of any research
directed screening or procedures
Subject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit

Exclusion Criteria

Subject has known active CNS involvement from AML
Subject is known to be positive for HIV. HIV testing is not required
Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate
Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to
Significant active cardiac disease within the previous 6 months including: New York Heart Association heart failure > class 2, unstable angina, or myocardial infarction
Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia
Subject has a malabsorption syndrome or other condition that precludes enteral route
of administration. This includes history of inflammatory bowel disease (e.g
Crohn's disease, ulcerative colitis), celiac disease (e.g. sprue), prior
gastrectomy or upper bowel removal, or any other gastrointestinal disorder or
defect that would interfere with the absorption, distribution, metabolism or
excretion of the study drug and/or predispose the subject to an increased risk
of gastrointestinal toxicity
Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). Uncontrolled is defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment
Subject has a history of other malignancies prior to study entry, with the exception
of
Adequately treated in situ carcinoma of the breast or cervix uteri
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
Prostate cancer not requiring therapy beyond hormonal therapy
Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
Subject has a white blood cell count > 25 × 109/L. Note: hydroxyurea or apheresis are
permitted to meet this criterion
Any subject who is a candidate for intensive induction therapy and agrees to receive this therapy
Pregnant or breast-feeding females. A pregnancy test will be obtained at the time of screening
Known or suspected hypersensitivity to azacitidine or mannitol
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note